- Email: [email protected]
Abstract: S1-8 OMEGA-3 FATTY ACIDS AND ARRHYTHMIA
- Pre-meeting symposia - Nutrition, Lifestyle, and Atherosclerosis Abstract: S1-8 Citation: Atherosclerosis Supplement 2009, Vol. 10, Issue 2
OMEGA-3 FATTY ACIDS AND ARRHYTHMIA R Marchioli Consorzio Mario Negri Sud GISSI-Prevenzione demonstrated that n-3 polyunsaturated fatty acids (PUFA) in 11,323 patients with recent myocardial infarction (MI) and preserved ventricular function significantly reduced death+nonfatal MI and stroke. In post-hoc analyses, such benefit was attributable to the significant reduction of death (20%), CV death (30%), and sudden cardiac death (SCD) (44%), nonfatal MI and stroke being nonsignificantly reduced. The benefit on death appeared early after randomization and was paralleled by a benefit on SCD. GISSI Heart Failure tested the antiarrhythmic hypothesis for n-3 PUFA in a large-scale, randomized, double-blind study in patients with symptomatic HF. Patients with NYHA classes II to IV HF, receiving optimized recommended therapy, have been recruited in a nation-wide network and randomly allocated to n-3 PUFA1 g daily (n=3494) or the corresponding placebo (n=3481). Patients were followed for a median of 3·9 years. 955 (27%) patients died in the n-3 PUFA group and 1014 (29%) in the placebo group (adjusted hazard ratio [HR] 0·91 [95·5% CI 0·833–0·998], p=0·041). 1981 (57%) patients in the n-3 PUFA group and 2053 (59%) in the placebo group died or were admitted to hospital for CV reasons (adjusted HR 0·92 [99% CI 0·849–0·999], p=0·009). In absolute terms, 56 patients needed to be treated for 3·9 years to avoid one death or 44 to avoid one death or admission to hospital for CV reason. In both groups, gastrointestinal disorders were the most frequent adverse reaction (96 [3%] n-3 PUFA vs 92 [3%] placebo group). Conclusion: A simple and safe treatment with n-3 PUFA can decrease the arrhythmic burden in patients with HF in a context of usual care. GISSI-HF is an independent study. SPA, Pfizer, Sigma Tau, and AstraZeneca concurred to fund the study. SPA provided the experimental treatment.
OMEGA-3 FATTY ACIDS AND ARRHYTHMIA R Marchioli Consorzio Mario Negri Sud GISSI-Prevenzione demonstrated that n-3 polyunsaturated fatty acids (PUFA) in 11,323 patients with recent myocardial infarction (MI) and preserved ventricular function significantly reduced death+nonfatal MI and stroke. In post-hoc analyses, such benefit was attributable to the significant reduction of death (20%), CV death (30%), and sudden cardiac death (SCD) (44%), nonfatal MI and stroke being nonsignificantly reduced. The benefit on death appeared early after randomization and was paralleled by a benefit on SCD. GISSI Heart Failure tested the antiarrhythmic hypothesis for n-3 PUFA in a large-scale, randomized, double-blind study in patients with symptomatic HF. Patients with NYHA classes II to IV HF, receiving optimized recommended therapy, have been recruited in a nation-wide network and randomly allocated to n-3 PUFA1 g daily (n=3494) or the corresponding placebo (n=3481). Patients were followed for a median of 3·9 years. 955 (27%) patients died in the n-3 PUFA group and 1014 (29%) in the placebo group (adjusted hazard ratio [HR] 0·91 [95·5% CI 0·833–0·998], p=0·041). 1981 (57%) patients in the n-3 PUFA group and 2053 (59%) in the placebo group died or were admitted to hospital for CV reasons (adjusted HR 0·92 [99% CI 0·849–0·999], p=0·009). In absolute terms, 56 patients needed to be treated for 3·9 years to avoid one death or 44 to avoid one death or admission to hospital for CV reason. In both groups, gastrointestinal disorders were the most frequent adverse reaction (96 [3%] n-3 PUFA vs 92 [3%] placebo group). Conclusion: A simple and safe treatment with n-3 PUFA can decrease the arrhythmic burden in patients with HF in a context of usual care. GISSI-HF is an independent study. SPA, Pfizer, Sigma Tau, and AstraZeneca concurred to fund the study. SPA provided the experimental treatment.